Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.

Diabetes research and clinical practice - 1 Jul 2007

Zhang Huijuan, Liu Xiaomin, Kuang Hongyu, Yi Ran, Xing Houxun

Abstract excerpt

To investigate the effects of sulfonylurea receptor 1 (SUR1) exon 33 (TCC-->GCC, S1369A) polymorphism on responsiveness to gliclazide. About 115 patients with type 2 diabetes were treated with gliclazide for 8 weeks. SUR1 genotypes were tested by Taqman-PCR. After gliclazide treatment, there was association between T/G polymorphism and decrease of HbA1c. G carriers were more sensitive to gliclazide and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP-Binding Cassette Transporters
Share to Blood Glucose

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycated Hemoglobin

Share to Hypoglycemic Agents

Share to Potassium Channels

Share to Potassium Channels, Inwardly Rectifying

Share to Receptors, Drug

Share to Sulfonylurea Receptors

Source

Identifiers

PMID: 17118480
DOI: 10.1016/j.diabres.2006.10.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.PMID 17118480Read ↗

CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.Semantic proximity Read ↗

Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.Semantic proximity Read ↗

KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.Semantic proximity Read ↗

Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes.Semantic proximity Read ↗

Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms.Semantic proximity Read ↗

CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.Semantic proximity Read ↗

Association between<i>TCF7L2</i>Genotype and Glycemic Control in Diabetic Patients Treated with GliclazideSemantic proximity Read ↗

Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population.Semantic proximity Read ↗

Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China.Semantic proximity Read ↗

[Study on the relationship between sulfonylurea receptor 1 gene polymorphism and type 2 diabetes mellitus].Semantic proximity Read ↗

Influence of the SLCO1B3 Gene on Sulfonylurea Failure in Patients with Type 2 Diabetes in China.Semantic proximity Read ↗

Effective treatment of diabetes caused by activating ABCC8/SUR1 mutation with glimepiride.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.